COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled with a GLP-1...
Atos Advances AI-Ready Digital Transformation with Lumen Network as a Service Irving, Texas, USA – March 31, 2026 – Atos,...
REHOVOT, Israel and HOBOKEN, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- Kamada Ltd. (the “Company”) (NASDAQ: KMDA; TASE: KMDA.TA), a...
Expanding nucleic acid delivery business with new applicationsOngoing optimization of cost structureAdvancing plans for spin-off of nucleic acid delivery business...
National survey of providers and care team professionals reveals strong support for VBC initiatives and reveals the operational barriers and...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS...
NORTHAMPTON, MA / ACCESS Newswire / March 31, 2026 / Home dialysis is transforming kidney care in the remote landscapes...
SAN ANTONIO, TX / ACCESS Newswire / March 31, 2026 / Tivic Health Systems, Inc. (Nasdaq:TIVC), a clinical-stage immunotherapeutics company,...
First-in-class metal-modulating epigenetic therapy targeting iron-dependent pathways with preclinical efficacy and a favorable GLP safety profile. MIAMI, FL / ACCESS...
A Double Wheat Brew that Surges with Big, Shocking Citrus, Shock Top High Voltage is Boldly Strong at 9.6% ABV...
Announces Seven Year Extension of Proton Therapy Lease Agreement with Orlando Health Through 2033 Conference Call Scheduled for 12:00 PM...
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat...
TNX-4800 is a long-acting anti-Borrelia burgdorferi OspA human monoclonal antibody in development as a single-dose Lyme prophylactic Phase 1 study of...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney...
JERSEY CITY, N.J., March 31, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused...
PXL-770 (now SCY-770) is a clinical stage, well-characterized oral therapy designed to address the underlying drivers of ADPKD by reducing...
March 31, 2026News Release KDIGO publishes 2026 Clinical Practice Guideline Draft for Acute Kidney Injury and Acute Kidney Disease COPENHAGEN,...
CDMO division has successfully completed Stage 1 under a development contractVancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - March 31,...
Brown's new book arrives as reshoring, tariffs, supply-chain realignment, and factory investment reshape the U.S. industrial economy NEW YORK CITY,...